CS
RLAY icon

Credit Suisse’s Relay Therapeutics RLAY Stock Holding History

Credit Suisse’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$687K Hold
82,750
– – ﹤0.01% 2483
2023
Q4 		$911K Sell
82,750
-6,246
-7% -$52.7K ﹤0.01% 2394
2023
Q3 		$748K Sell
88,996
-29,573
-25% -$318K ﹤0.01% 2468
2023
Q2 		$1.49M Buy
118,569
+37,107
+46% +$462K ﹤0.01% 2124
2023
Q1 		$1.34M Buy
81,462
+5,346
+7% +$95.9K ﹤0.01% 2129
2022
Q4 		$1.14M Buy
76,116
+11,608
+18% +$222K ﹤0.01% 2252
2022
Q3 		$1.44M Buy
64,508
+6,497
+11% +$143K ﹤0.01% 2062
2022
Q2 		$971K Buy
58,011
+25,033
+76% +$536K ﹤0.01% 2408
2022
Q1 		$987K Buy
32,978
+2,760
+9% +$67K ﹤0.01% 2561
2021
Q4 		$928K Sell
30,218
-2,643
-8% -$83.5K ﹤0.01% 3379
2021
Q3 		$1.04M Sell
32,861
-974
-3% -$32.8K ﹤0.01% 3313
2021
Q2 		$1.24M Buy
33,835
+4,521
+15% +$149K ﹤0.01% 3221
2021
Q1 		$1.01M Sell
29,314
-21,909
-43% -$951K ﹤0.01% 3316
2020
Q4 		$2.13M Buy
+51,223
New +$2.32M ﹤0.01% 2775

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Credit Suisse's RLAY Position: Q1 2024 in Review

Credit Suisse held its Relay Therapeutics (RLAY) position steady in Q1 2024 at 82,750 shares worth $687K. The position accounts for ﹤0.01% of the portfolio, ranked #2483.

Credit Suisse first reported a position in RLAY in Q4 2020 and has held it in 14 quarters since. The position peaked at $2.13M in Q4 2020. 189 funds tracked by Wall St. Rank hold RLAY as of Q1 2024.

  • Credit Suisse held 82,750 shares of Relay Therapeutics worth $687K as of Q1 2024.
  • Credit Suisse left its Relay Therapeutics share count unchanged in Q1 2024.
  • Relay Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2483 holding.
  • Credit Suisse first reported a position in Relay Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Credit Suisse's Relay Therapeutics position peaked at $2.13M in Q4 2020.
  • 189 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.